| Unique ID issued by UMIN | UMIN000060977 |
|---|---|
| Receipt number | R000069255 |
| Scientific Title | Non-Invasive Diagnosis and Prognostic Modeling Study in Steatotic Liver Disease in JAPAN |
| Date of disclosure of the study information | 2026/03/31 |
| Last modified on | 2026/03/18 20:52:33 |
Development of a Non-Invasive Diagnostic Algorithm and Prognostic Prediction Model for Steatotic Liver Disease in JAPAN:
A Multicenter Retrospective Large-Scale Database Study
A Multicenter Study Using Non-Invasive Tests to Predict Long-Term Outcomes in Fatty Liver Disease in JAPAN
Non-Invasive Diagnosis and Prognostic Modeling Study in Steatotic Liver Disease in JAPAN
SLD-NILDA JAPAN Study
| Japan |
Patients with Steatotic Liver Disease(SLD)
| Medicine in general | Hepato-biliary-pancreatic medicine |
Others
NO
The objective of this study is to establish a large-scale NILDA database in patients with steatotic liver disease (SLD) by integrating patient demographics, laboratory findings, and histopathological assessments. Using this database as a foundation, we aim to comprehensively re-evaluate non-invasive diagnostic algorithms for SLD and to develop prognostic prediction models for overall survival through multifaceted analyses.
Efficacy
Prognosis of Steatotic Liver Disease Using the NILDA Database
1) To develop predictive models for the progression of liver injury and hepatocarcinogenesis in patients with steatotic liver disease (SLD) using the NILDA database.
2) To evaluate the diagnostic performance of NILDA for liver fibrosis and to determine optimal cutoff values, using liver biopsy and magnetic resonance elastography (MRE) as reference standards.
3) To evaluate the diagnostic performance of NILDA for hepatic steatosis and to determine optimal cutoff values, using liver biopsy and magnetic resonance imaging-proton density fat fraction (MRI-PDFF) as reference standards.
4) To develop a predictive model for identifying patients with high-risk metabolic dysfunction-associated steatohepatitis (MASH), defined as a NAFLD activity score >=4 and liver fibrosis stage >=2.
Observational
| Not applicable |
| Not applicable |
Male and Female
Patients diagnosed with SLD or suspected SLD
Definition of suspected SLD: patients meeting at least one of the following criteria
Patients with cardiometabolic risk factors
Patients with liver function abnormalities
1) Patients deemed ineligible by the attending physician
2) Patients who have declined participation following public disclosure of the study
2000
| 1st name | Kuroda |
| Middle name | |
| Last name | Hidekatsu |
Iwate Medical University
Division of Gastroenterology and Hepatology, Department of Internal Medicine
028-3695
2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate, Japan
019-613-7111
hikuro@iwate-med.ac.jp
| 1st name | Abe |
| Middle name | |
| Last name | Tamami |
Iwate Medical University
Division of Gastroenterology and Hepatology, Department of Internal Medicine
028-3695
2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate, Japan
019-613-7111
mokosantokosan@yahoo.co.jp
Iwate Medical University
Iwate Medical University
Other
Ethics Committee of Iwate Medical University
2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate, Japan
019-613-7111
kenkyu-rinri@j.iwate-med.ac.jp
NO
岩手医科大学
| 2026 | Year | 03 | Month | 31 | Day |
Unpublished
Preinitiation
| 2026 | Year | 02 | Month | 19 | Day |
| 2025 | Year | 04 | Month | 18 | Day |
| 2026 | Year | 04 | Month | 01 | Day |
| 2030 | Year | 03 | Month | 31 | Day |
N/A
| 2026 | Year | 03 | Month | 18 | Day |
| 2026 | Year | 03 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069255